Dana Farber Cancer Institute (DFCI) (Adults and Pediatrics) — Boston, Massachusetts

Public research footprint of Dana Farber Cancer Institute (DFCI) (Adults and Pediatrics), compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Resectable Pancreatic Ductal Adenocarcinoma (PDAC) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Head and Neck Neoplasms · Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Recently updated registry entries

NCT07252232 — Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal… (Recruiting)
NCT04554914 — A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV)… (Active Not Recruiting)
NCT06003231 — A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Dana Farber Cancer Institute (DFCI) (Adults and Pediatrics)?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 05, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.